Core Points - A shareholder class action lawsuit has been filed against Metagenomi, Inc. alleging that the company made materially false and misleading statements regarding its collaboration agreement with Moderna, which harmed investors [1] - The lawsuit specifically targets investors who purchased shares of Metagenomi on or after February 13, 2024, and experienced significant losses [2] - The deadline for investors to request to be appointed as lead plaintiff in the case is November 25, 2024 [3]

Core Points - Metagenomi, Inc. (NASDAQ: MGX) is facing a class action lawsuit following the termination of its collaboration with Moderna, which was a significant aspect of its business model [3][4] - The company completed its initial public offering (IPO) on February 13, 2024, selling 6.25 million shares at $15 per share, but the stock price fell from $7.04 to $6.17 within a day after the announcement of the collaboration termination [3] Group 1 - The lawsuit is on behalf of shareholders who purchased stock during the class period from February 9 to 13, 2024, related to Metagenomi's IPO [2][4] - The termination of the collaboration with Moderna was unexpected and raised concerns about Metagenomi's future prospects [3] - The Gross Law Firm is leading the class action, emphasizing its commitment to protecting investors' rights against deceitful practices [5] Group 2 - Shareholders are encouraged to register for the class action by November 25, 2024, to potentially become lead plaintiffs [4] - The firm offers portfolio monitoring software to keep registered shareholders updated on the case's progress [4] - The lawsuit highlights the importance of accurate disclosures and the impact of misleading statements on stock performance [5]

NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Metagenomi, Inc. (“Metagenomi” or the “Company”) (NASDAQ: MGX) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired Metagenomi securities pursuant and/or traceable to Metagenomi's registration statement for the initial public of ...

PHILADELPHIA, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Metagenomi Inc. (“Metagenomi” or the “Company”) (NASDAQ: MGX) on behalf of purchasers of Metagenomi securities between February 6, 2024 and September 26, 2024, inclusive (the “Class Period”). Investor Deadline: Investors who purchased or acquired METAGENOMI securities during the Class Period may, no later than NOVEMBER 25, 2024, seek to be appointed as a lead pla ...

Group 1 - The lawsuit is on behalf of shareholders who purchased Metagenomi, Inc. (NASDAQ: MGX) shares during the initial public offering (IPO) period from February 9 to 13, 2024 [1] - Metagenomi's IPO involved selling 6.25 million shares at a price of $15 per share, and the company claimed a significant partnership with Moderna, which was a key aspect of its business model [2] - The collaboration with Moderna was terminated on May 1, 2024, leading to a decline in Metagenomi's stock price from $7.04 to $6.17 per share within a day [2] Group 2 - Shareholders are encouraged to register for the class action lawsuit by November 25, 2024, to potentially become lead plaintiffs and receive updates on the case [3] - The Gross Law Firm aims to protect investors' rights and seeks recovery for losses incurred due to misleading statements or omissions by companies [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Metagenomi, Inc. stock during its IPO of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Metagenomi stock between February 9 and 13, 2024, may be eligible for compensation without any out-of-pocket costs through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 25, 2024 [2] - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3] Group 2: Company Background and Allegations - Metagenomi presented itself as a "genetic medicines company" with a significant partnership with Moderna during its IPO [4] - The collaboration with Moderna included a Strategic Collaboration and License Agreement established on October 29, 2021, which involved multiple research programs [4] - Following the IPO, Metagenomi announced the termination of its collaboration with Moderna on May 1, 2024, leading to claims of investor damages when the true details became public [4]

NEW YORK, Nov. 2, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of Metagenomi, Inc. (NASDAQ: MGX) pursuant and/or traceable to the Company's initial public offering conducted between February 9 and 13, 2024 (the "IPO"), of the important November 25, 2024 lead plaintiff deadline.So what: If you purchased Metagenomi stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.What to do ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Metagenomi, Inc. stock during its IPO of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Company Overview - Metagenomi, Inc. is described as a "genetic medicines company" that had a collaboration with Moderna, a leading Covid-19 vaccine company [4] - The company completed its IPO on February 13, 2024, selling 6.25 million shares at a price of $15 per share [4] Group 2: Legal Proceedings - A class action lawsuit has been filed against Metagenomi following the termination of its collaboration agreement with Moderna on May 1, 2024, which allegedly caused investor damages [4] - Investors who purchased Metagenomi stock during the IPO may be entitled to compensation through a contingency fee arrangement [1][2] Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest ever against a Chinese company [3] - The firm has been consistently ranked among the top firms for securities class action settlements since 2013, recovering hundreds of millions for investors [3]

Core Insights - A lawsuit has been filed against Metagenomi, Inc. (NASDAQ: MGX) for alleged violations of securities laws, with a deadline for affected investors to act by November 25, 2024 [1][4]. Company Overview - Metagenomi, Inc. completed its initial public offering (IPO) on February 13, 2024, selling approximately 6.25 million shares at $15 per share [3]. - Following the termination of a collaboration agreement with Moderna on May 1, 2024, shares of Metagenomi, Inc. have declined by over 85% [3]. Legal Proceedings - The lawsuit claims that the defendants made materially false and misleading statements regarding the company's business and prospects, seeking to compensate investors who purchased shares during the IPO and suffered losses [4]. - Investors who incurred losses exceeding $100,000 are encouraged to contact the Shareholders Foundation for assistance [2].

Core Viewpoint - The Gross Law Firm is notifying shareholders of Metagenomi, Inc. regarding a class action lawsuit related to the company's initial public offering and subsequent termination of its collaboration with Moderna, which has led to a significant decline in stock price [1][3]. Group 1: Company Overview - Metagenomi, Inc. is characterized as a "genetic medicines company" that had a strategic collaboration with Moderna, a leading Covid-19 vaccine company [3]. - The company completed its initial public offering on February 13, 2024, selling 6.25 million shares at a price of $15 per share [3]. Group 2: Allegations and Impact - The lawsuit alleges that Metagenomi misled investors regarding its collaboration with Moderna, which was a critical aspect of its business model [3]. - Following the announcement of the termination of the collaboration on May 1, 2024, Metagenomi's stock price fell from $7.04 per share to $6.17 per share within a day, indicating a significant market reaction to the news [3]. Group 3: Legal Proceedings - Shareholders who purchased shares during the class period from February 9 to 13, 2024, are encouraged to register for the class action lawsuit, with a deadline for lead plaintiff appointment set for November 25, 2024 [2][4]. - The Gross Law Firm aims to protect the rights of investors who have suffered losses due to misleading statements or omissions by the company [5].